Apr 11, 2024 7:00 am EDT Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
Apr 10, 2024 5:00 pm EDT Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
Apr 10, 2024 7:00 am EDT Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
Apr 4, 2024 4:30 pm EDT Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
Apr 2, 2024 7:00 am EDT Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Mar 25, 2024 7:00 am EDT Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
Mar 22, 2024 4:30 pm EDT Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
Mar 19, 2024 7:00 am EDT Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
Mar 15, 2024 4:30 pm EDT New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
